A Phase 2 interventional study of 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride and Mannitol in Atrial Fibrillation and Atrial Flutter, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Atrial Fibrillation with a site in Russia — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Russia.
Among the 20 studies in Atrial Fibrillation with a site in Russia, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 10th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →9 of the 20 studies in Atrial Fibrillation with a site in Russia are open now. Recruiting first, the newest first:
Bakulev Scientific Center of Cardiovascular Surgery · Sites in Russia
Ages 18–70
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 18+
Bakulev Scientific Center of Cardiovascular Surgery · Sites in Russia
Ages 18–80
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Sites in Russia
Ages 18+
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Ages 18–80
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 158 across the 11 interventional studies, 1,600 across the 8 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
6 of the studies in Atrial Fibrillation with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253000Bakulev Scientific Center of Cardiovascular SurgeryRadiofrequency and Cryoablation of the Posterior Wall of the Left Atrium | 2026-12-30 |
| NCT06540352National Medical Research Center for Cardiology, Ministry of Health of Russian FederationA Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form | 2026-12-31 |
| NCT04347187National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-2 | 2026-12-31 |
| NCT07487714Tomsk National Research Medical Center of the Russian Academy of SciencesComparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration | 2027-05 |
| NCT07063381Bakulev Scientific Center of Cardiovascular SurgeryLow-frequency Electrical Stimulation for Cognitive Enhancement in Atrial Fibrillation | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies in Atrial Fibrillation with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Refralon® tablets in two different doses (1 or 2 tablets per day) will be evaluated vs. placebo in patients with persistent atrial fibrillation/flutter after synus rhythm restoration in order to prevent recurrence of arrhythmia. Efficacy and safety of Refralon® tablets will be studied, its optimal dose will be selected and its pharmacokinetics will be evaluated in 14 days, 1, 3 and 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mannitol
Drug: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
Drug: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
Placebo in tablets
Proportion of subjects in the group who were shown to maintain sinus rhythm at the end of 6 months of follow-up;
Time frame: 6 months
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation